Cargando…
Adjuvant bevacizumab for melanoma patients at high risk of recurrence: survival analysis of the AVAST-M trial
| Autores principales: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Oxford University Press
2019
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6938599/ https://www.ncbi.nlm.nih.gov/pubmed/31430371 http://dx.doi.org/10.1093/annonc/mdz237 |
| _version_ | 1783484064053854208 |
|---|---|
| author | Corrie, P G Marshall, A Nathan, P D Lorigan, P Gore, M Tahir, S Faust, G Kelly, C G Marples, M Danson, S J Marshall, E Houston, S J Board, R E Waterston, A M Nobes, J P Harries, M Kumar, S Goodman, A Dalgleish, A Martin-Clavijo, A Westwell, S Casasola, R Chao, D Maraveyas, A Patel, P M Ottensmeier, C H Farrugia, D Humphreys, A Eccles, B Young, G Barker, E O Harman, C Weiss, M Myers, K A Chhabra, A Rodwell, S H Dunn, J A Middleton, M R |
| author_facet | Corrie, P G Marshall, A Nathan, P D Lorigan, P Gore, M Tahir, S Faust, G Kelly, C G Marples, M Danson, S J Marshall, E Houston, S J Board, R E Waterston, A M Nobes, J P Harries, M Kumar, S Goodman, A Dalgleish, A Martin-Clavijo, A Westwell, S Casasola, R Chao, D Maraveyas, A Patel, P M Ottensmeier, C H Farrugia, D Humphreys, A Eccles, B Young, G Barker, E O Harman, C Weiss, M Myers, K A Chhabra, A Rodwell, S H Dunn, J A Middleton, M R |
| author_sort | Corrie, P G |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-6938599 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2019 |
| publisher | Oxford University Press |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-69385992020-01-07 Adjuvant bevacizumab for melanoma patients at high risk of recurrence: survival analysis of the AVAST-M trial Corrie, P G Marshall, A Nathan, P D Lorigan, P Gore, M Tahir, S Faust, G Kelly, C G Marples, M Danson, S J Marshall, E Houston, S J Board, R E Waterston, A M Nobes, J P Harries, M Kumar, S Goodman, A Dalgleish, A Martin-Clavijo, A Westwell, S Casasola, R Chao, D Maraveyas, A Patel, P M Ottensmeier, C H Farrugia, D Humphreys, A Eccles, B Young, G Barker, E O Harman, C Weiss, M Myers, K A Chhabra, A Rodwell, S H Dunn, J A Middleton, M R Ann Oncol Corrigenda Oxford University Press 2019-12 2019-08-20 /pmc/articles/PMC6938599/ /pubmed/31430371 http://dx.doi.org/10.1093/annonc/mdz237 Text en © The Author(s) 2019. Published by Oxford University Press on behalf of the European Society for Medical Oncology. http://creativecommons.org/licenses/by/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited. |
| spellingShingle | Corrigenda Corrie, P G Marshall, A Nathan, P D Lorigan, P Gore, M Tahir, S Faust, G Kelly, C G Marples, M Danson, S J Marshall, E Houston, S J Board, R E Waterston, A M Nobes, J P Harries, M Kumar, S Goodman, A Dalgleish, A Martin-Clavijo, A Westwell, S Casasola, R Chao, D Maraveyas, A Patel, P M Ottensmeier, C H Farrugia, D Humphreys, A Eccles, B Young, G Barker, E O Harman, C Weiss, M Myers, K A Chhabra, A Rodwell, S H Dunn, J A Middleton, M R Adjuvant bevacizumab for melanoma patients at high risk of recurrence: survival analysis of the AVAST-M trial |
| title | Adjuvant bevacizumab for melanoma patients at high risk of recurrence: survival analysis of the AVAST-M trial |
| title_full | Adjuvant bevacizumab for melanoma patients at high risk of recurrence: survival analysis of the AVAST-M trial |
| title_fullStr | Adjuvant bevacizumab for melanoma patients at high risk of recurrence: survival analysis of the AVAST-M trial |
| title_full_unstemmed | Adjuvant bevacizumab for melanoma patients at high risk of recurrence: survival analysis of the AVAST-M trial |
| title_short | Adjuvant bevacizumab for melanoma patients at high risk of recurrence: survival analysis of the AVAST-M trial |
| title_sort | adjuvant bevacizumab for melanoma patients at high risk of recurrence: survival analysis of the avast-m trial |
| topic | Corrigenda |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6938599/ https://www.ncbi.nlm.nih.gov/pubmed/31430371 http://dx.doi.org/10.1093/annonc/mdz237 |
| work_keys_str_mv | AT corriepg adjuvantbevacizumabformelanomapatientsathighriskofrecurrencesurvivalanalysisoftheavastmtrial AT marshalla adjuvantbevacizumabformelanomapatientsathighriskofrecurrencesurvivalanalysisoftheavastmtrial AT nathanpd adjuvantbevacizumabformelanomapatientsathighriskofrecurrencesurvivalanalysisoftheavastmtrial AT loriganp adjuvantbevacizumabformelanomapatientsathighriskofrecurrencesurvivalanalysisoftheavastmtrial AT gorem adjuvantbevacizumabformelanomapatientsathighriskofrecurrencesurvivalanalysisoftheavastmtrial AT tahirs adjuvantbevacizumabformelanomapatientsathighriskofrecurrencesurvivalanalysisoftheavastmtrial AT faustg adjuvantbevacizumabformelanomapatientsathighriskofrecurrencesurvivalanalysisoftheavastmtrial AT kellycg adjuvantbevacizumabformelanomapatientsathighriskofrecurrencesurvivalanalysisoftheavastmtrial AT marplesm adjuvantbevacizumabformelanomapatientsathighriskofrecurrencesurvivalanalysisoftheavastmtrial AT dansonsj adjuvantbevacizumabformelanomapatientsathighriskofrecurrencesurvivalanalysisoftheavastmtrial AT marshalle adjuvantbevacizumabformelanomapatientsathighriskofrecurrencesurvivalanalysisoftheavastmtrial AT houstonsj adjuvantbevacizumabformelanomapatientsathighriskofrecurrencesurvivalanalysisoftheavastmtrial AT boardre adjuvantbevacizumabformelanomapatientsathighriskofrecurrencesurvivalanalysisoftheavastmtrial AT waterstonam adjuvantbevacizumabformelanomapatientsathighriskofrecurrencesurvivalanalysisoftheavastmtrial AT nobesjp adjuvantbevacizumabformelanomapatientsathighriskofrecurrencesurvivalanalysisoftheavastmtrial AT harriesm adjuvantbevacizumabformelanomapatientsathighriskofrecurrencesurvivalanalysisoftheavastmtrial AT kumars adjuvantbevacizumabformelanomapatientsathighriskofrecurrencesurvivalanalysisoftheavastmtrial AT goodmana adjuvantbevacizumabformelanomapatientsathighriskofrecurrencesurvivalanalysisoftheavastmtrial AT dalgleisha adjuvantbevacizumabformelanomapatientsathighriskofrecurrencesurvivalanalysisoftheavastmtrial AT martinclavijoa adjuvantbevacizumabformelanomapatientsathighriskofrecurrencesurvivalanalysisoftheavastmtrial AT westwells adjuvantbevacizumabformelanomapatientsathighriskofrecurrencesurvivalanalysisoftheavastmtrial AT casasolar adjuvantbevacizumabformelanomapatientsathighriskofrecurrencesurvivalanalysisoftheavastmtrial AT chaod adjuvantbevacizumabformelanomapatientsathighriskofrecurrencesurvivalanalysisoftheavastmtrial AT maraveyasa adjuvantbevacizumabformelanomapatientsathighriskofrecurrencesurvivalanalysisoftheavastmtrial AT patelpm adjuvantbevacizumabformelanomapatientsathighriskofrecurrencesurvivalanalysisoftheavastmtrial AT ottensmeierch adjuvantbevacizumabformelanomapatientsathighriskofrecurrencesurvivalanalysisoftheavastmtrial AT farrugiad adjuvantbevacizumabformelanomapatientsathighriskofrecurrencesurvivalanalysisoftheavastmtrial AT humphreysa adjuvantbevacizumabformelanomapatientsathighriskofrecurrencesurvivalanalysisoftheavastmtrial AT ecclesb adjuvantbevacizumabformelanomapatientsathighriskofrecurrencesurvivalanalysisoftheavastmtrial AT youngg adjuvantbevacizumabformelanomapatientsathighriskofrecurrencesurvivalanalysisoftheavastmtrial AT barkereo adjuvantbevacizumabformelanomapatientsathighriskofrecurrencesurvivalanalysisoftheavastmtrial AT harmanc adjuvantbevacizumabformelanomapatientsathighriskofrecurrencesurvivalanalysisoftheavastmtrial AT weissm adjuvantbevacizumabformelanomapatientsathighriskofrecurrencesurvivalanalysisoftheavastmtrial AT myerska adjuvantbevacizumabformelanomapatientsathighriskofrecurrencesurvivalanalysisoftheavastmtrial AT chhabraa adjuvantbevacizumabformelanomapatientsathighriskofrecurrencesurvivalanalysisoftheavastmtrial AT rodwellsh adjuvantbevacizumabformelanomapatientsathighriskofrecurrencesurvivalanalysisoftheavastmtrial AT dunnja adjuvantbevacizumabformelanomapatientsathighriskofrecurrencesurvivalanalysisoftheavastmtrial AT middletonmr adjuvantbevacizumabformelanomapatientsathighriskofrecurrencesurvivalanalysisoftheavastmtrial |